Literature DB >> 17660220

Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis.

S I Nihtyanova1, G M Brough, C M Black, C P Denton.   

Abstract

BACKGROUND: Vascular damage is a key pathological process in systemic sclerosis (SSc) and accounts for significant disease-related morbidity. To determine the clinical burden of severe digital vasculopathy (SDV), we have reviewed hospital-based treatment for this important complication of SSc in a large single centre cohort.
METHODS: Cases were identified from a cohort of 1168 patients with a diagnosis of SSc who were reviewed during an 18-month period. Patients with recorded episodes of SDV-related complications (digital ulceration, critical digital ischaemia or digital gangrene), requiring surgical amputation, digital sympathectomy or admissions for intravenous prostacyclin or calcitonin gene related peptide (CGRP) and/or intravenous antibiotic treatment were identified.
RESULTS: From this large SSc cohort, 17.4% had SDV-related complications. Contrary to expectation, their frequency was significantly higher among the patients with the diffuse cutaneous subset of SSc (27.5%) compared with 13% among the patients with limited cutaneous SSc (p<0.0001). 16.6% had at least one recorded episode of digital ulcers, and 12% required at least one hospitalisation during the 18 months for treatment with intravenous prostacyclin/CGRP. Overall, there were 242 admissions with a mean duration of 6 days.
CONCLUSIONS: Digital vasculopathy is a serious complication of SSc contributing significant morbidity and often requiring hospital-based management.

Entities:  

Mesh:

Year:  2007        PMID: 17660220     DOI: 10.1136/ard.2007.072686

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  32 in total

Review 1.  Raynaud's phenomenon (secondary).

Authors:  Ariane Herrick; Lindsay Muir
Journal:  BMJ Clin Evid       Date:  2014-10-14

Review 2.  Is there evidence for vasculitis in systemic sclerosis?

Authors:  Lesley Ann Saketkoo; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

3.  Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost.

Authors:  Paola Caramaschi; Alessandra Dalla Gassa; Daniele Prati; Giovanni Barausse; Ilaria Tinazzi; Viviana Ravagnani; Silvia Confente; Domenico Biasi
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

4.  Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis.

Authors:  Predrag Ostojic; Natasa Stojanovski
Journal:  Rheumatol Int       Date:  2016-12-22       Impact factor: 2.631

5.  Relationship between body composition and both cardiovascular risk factors and lung function in systemic sclerosis.

Authors:  Paola Caramaschi; Domenico Biasi; Cristian Caimmi; Giovanni Barausse; Davide Gatti; Marcello Ferrari; Sara Pieropan; Dania Sabbagh; Silvano Adami
Journal:  Clin Rheumatol       Date:  2013-09-20       Impact factor: 2.980

Review 6.  Evidence-based management of Raynaud's phenomenon.

Authors:  Ariane L Herrick
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-11-20       Impact factor: 5.346

7.  Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis.

Authors:  Andreu Fernández-Codina; Mikameh Kazem; Janet E Pope
Journal:  Clin Rheumatol       Date:  2020-02-03       Impact factor: 2.980

Review 8.  Raynaud's phenomenon (secondary).

Authors:  Ariane Herrick
Journal:  BMJ Clin Evid       Date:  2008-09-26

9.  Digital ischemic loss in systemic sclerosis.

Authors:  Umaima Marvi; Lorinda Chung
Journal:  Int J Rheumatol       Date:  2010-08-24

10.  Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series.

Authors:  Julie J Paik; Ram Hirpara; Jennifer A Heller; Laura K Hummers; Fredrick M Wigley; Ami A Shah
Journal:  Semin Arthritis Rheum       Date:  2016-03-31       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.